Dividend Distribution - The proposed cash dividend distribution is 0.8 CNY per 10 shares, totaling 60,807,649.04 CNY (including tax) for the year 2024, which accounts for 60.15% of the net profit attributable to shareholders [6]. - The total cash dividend for 2024, including the mid-year dividend of 251,408,449.24 CNY, amounts to 312,216,098.28 CNY (including tax) [6]. - The company implemented a mid-term dividend of 251 million yuan in 2024, with a commitment to maintain a minimum of 50% of net profit as cash dividends from 2024 to 2026 [91]. - The cumulative cash dividend over the last three accounting years was CNY 990,583,068 [191]. - The average net profit over the last three accounting years was CNY 744,349,352, resulting in a cash dividend ratio of 133.08% [191]. Financial Performance - The company reported a revenue of RMB 1.5 billion for the fiscal year 2024, representing a year-over-year growth of 15% [16]. - The company's operating revenue for 2024 was CNY 22,357,610,195, a slight decrease of 0.36% compared to 2023 [24]. - Net profit attributable to shareholders decreased by 44.13% to CNY 519,063,405, primarily due to the increase in the number of new stores and goodwill impairment losses [26]. - The net cash flow from operating activities fell by 25.77% to CNY 2,026,458,797, attributed to reduced cash receipts from sales and increased payroll expenses from new store openings [26]. - Basic earnings per share dropped by 44.72% to CNY 0.68, reflecting the overall decline in profitability [25]. - The weighted average return on equity decreased to 7.84%, down from 13.91% in the previous year, indicating a significant reduction in efficiency [25]. Market Expansion and Strategy - The company plans to expand its market presence by opening 50 new stores across various provinces in 2024 [16]. - A strategic acquisition of a regional pharmacy chain is anticipated to enhance distribution capabilities and increase market share by 10% [16]. - The company aims to enhance its online-to-offline (O2O) model, targeting a 30% increase in online sales by the end of 2024 [16]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years [160]. - The company is exploring potential mergers and acquisitions to enhance growth opportunities [158]. Risk Management - The company has reported no significant risks that could materially affect its operations during the reporting period [8]. - The company has detailed various risks and countermeasures in the management discussion and analysis section of the report [8]. - The company emphasizes the importance of investor awareness regarding investment risks related to forward-looking statements [7]. - The company faces industry policy risks due to increasing regulatory scrutiny in the pharmaceutical retail sector, which could adversely affect its development if not managed properly [144]. - To mitigate market competition risks, the company will continue its digital transformation and improve operational efficiency through AI and big data technologies [144]. Operational Efficiency - The gross margin for the last quarter was reported at 35%, a slight improvement from 33% in the previous year [16]. - The company has allocated RMB 100 million for research and development in new drug formulations and delivery systems [16]. - The company reduced inventory turnover days to 94 days by the end of 2024, a decrease of 4 days year-on-year, while the proportion of centralized procurement sales increased to 72.4% [86]. - The company completed 479 non-operational procurement projects in 2024, achieving a cost reduction of over 16 million yuan, with a reduction rate of over 7% [86]. - The company is enhancing its quality and compliance management systems, establishing a four-level quality management structure [98]. Customer Engagement and Satisfaction - User data indicates an increase in active customers by 20% to 3 million in the last quarter [16]. - The company’s total membership reached 99.65 million by the end of 2024, with 30.34 million active members and a membership sales contribution exceeding 75% [90]. - Customer satisfaction ratings have improved, with a reported 90% satisfaction rate in recent surveys [160]. - The company has established a smart chronic disease management service system, with over 18.12 million people registered for chronic disease management services and 99.23 million self-testing services provided by the end of 2024 [82]. Corporate Governance - The company held 4 shareholder meetings during the reporting period, ensuring compliance with legal requirements and maintaining transparency in decision-making processes [149]. - The company disclosed a total of 89 announcements during the reporting period, adhering to legal obligations for accurate and timely information disclosure [150]. - The company has undergone a board election, resulting in the appointment of new directors including Xie Jiaqi and Liu Xiaoen [165]. - The company is committed to aligning its compensation practices with shareholder interests through board approval processes [164]. - The company continues to focus on governance and compliance through regular board elections and management reviews [165]. Research and Development - The company has invested 1.23 million RMB in environmental protection during the reporting period [199]. - Research and development expenses totaled 136,011,931, representing 0.61% of total revenue, with 98.52% of R&D costs capitalized [115]. - Investment in R&D has increased by 30%, focusing on innovative technologies and product development [161]. - The number of R&D personnel is 434, making up 1.08% of the total workforce [116]. - The company has developed 1,900 courses on its learning platform, with a total of over 769 million learning instances [179].

老百姓大药房连锁股份有限公司 2024年度非经营性资金占用及 其他关联资金往来情况的专项说明 2024年12月31日 关于老百姓大药房连锁股份有限公司 2024年度非经营性资金占用及其他关联资金往来情况的专项说明 安永华明（2025）专字第70053916_P03号 老百姓大药房连锁股份有限公司 老百姓大药房连锁股份有限公司董事会： 我们审计了老百姓大药房连锁股份有限公司的2024年度财务报表，包括2024年12月31日 的合并及公司资产负债表，2024年度的合并及公司利润表、股东权益变动表和现金流量表以 及相关财务报表附注，并于2025年4月29日出具了编号为安永华明（2025）审字第 70053916_P01号的无保留意见审计报告。 本专项说明仅供老百姓大药房连锁股份有限公司为2024年度报告披露使用，不适用于其 他用途。 A member firm of Ernst & Young Global Limited 1 关于老百姓大药房连锁股份有限公司 2024年度非经营性资金占用及其他关联资金往来情况的专项说明（续） 安永华明（2025）专字第70053916_P03号 老百姓大药房连锁股份有限公司 （本 ...

老百姓大药房连锁股份有限公司 已审财务报表 2024年度 老百姓大药房连锁股份有限公司 | | 页 | | 次 | | | --- | --- | --- | --- | --- | | 一、审计报告 | 1 | – | 6 | | | 二、已审财务报表 | | | | | | 合并资产负债表 | 7 | – | 9 | | | 合并利润表 | 10 | – | 11 | | | 合并股东权益变动表 | 12 | – | 13 | | | 合并现金流量表 | 14 | – | 15 | | | 公司资产负债表 | 16 | – | 18 | | | 公司利润表 | | 19 | | | | 公司股东权益变动表 | 20 | – | 21 | | | 公司现金流量表 | 22 | – | 23 | | | 财务报表附注 | 24 | – | 16 | 5 | | 三、补充资料 | | | | | | 1.非经常损益明细表 | | 1 | | | | 2.净资产收益率和每股收益 | | 1 | | | 目录 一、审计意见 我们审计了老百姓大药房连锁股份有限公司的财务报表，包括2024年12月31日的 合并及公司资 ...

老百姓大药房连锁股份有限公司 关于老百姓大药房连锁股份有限公司 募集资金年度存放与实际使用情况的鉴证报告 2024年12月31日 老百姓大药房连锁股份有限公司 目录 | 一、 | 关于老百姓大药房连锁股份有限公司募集资金存放 | 页次 | | --- | --- | --- | | | 与实际使用情况鉴证报告 | 1-2 | | 二、 | 老百姓大药房连锁股份有限公司关于2024年度 | | | | 募集资金存放与实际使用情况的专项报告 | 3-6 | | 三、 | 附表1：募集资金使用情况对照表 附表2：变更募集资金投资项目情况表 | 7-13 | 关于老百姓大药房连锁股份有限公司 募集资金存放与实际使用情况鉴证报告 A member firm of Ernst & Young Global Limited 1 安永华明（2025）专字第70053916_P02号 老百姓大药房连锁股份有限公司 老百姓大药房连锁股份有限公司董事会： 我们接受委托，对后附的老百姓大药房连锁股份有限公司2024年度募集资金存放 与实际使用情况的专项报告（"募集资金专项报告"）进行了鉴证。按照《上市公司 监管指引第2号——上市公司 ...

内部控制审计报告 老百姓大药房连锁股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计了 老百姓大药房连锁股份有限公司 2024 年 12 月 31 日的财务报告内部控制的有效性。 一、 企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价 指引》的规定，建立健全和有效实施内部控制，并评价其有效性是老百姓大药房连锁股份 有限公司董事会的责任。 二、 注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计意见， 并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、 内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于情况的变 化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部控制审 计结果推测未来内部控制的有效性具有一定风险。 四、 财务报告内部控制审计意见 我们认为，老百姓大药房连锁股份有限公司于 2024 年 12 月 31 日按照《企业内部控 制基本规范》和相关规定在所有重大方面保持了有效的财务报告内部控制。 安永华明（20 ...

老百姓（603883）公告，2025年第一季度营收为54.35亿元，同比下降1.88%；净利润为2.51亿元，同比 下降21.98%。 ...

Core Viewpoint - The cancellation of the "refund only" policy by e-commerce platforms represents a significant regression in consumer rights, leading to increased risks and challenges for consumers in the current shopping environment [4][5][11]. Group 1: Consumer Rights and E-commerce Dynamics - The removal of the "refund only" option has shifted the balance of power towards merchants, making it harder for consumers to contest poor-quality products [3][4]. - This change is perceived as a systematic trial of consumer limits, undermining previously established protections that allowed consumers to voice their grievances [4][11]. - The competitive landscape of e-commerce has evolved, with major platforms becoming less concerned about consumer feedback, resulting in less favorable pricing and more complex promotional rules [7][9]. Group 2: Consumer Response and Market Trends - Despite the challenges, consumers are beginning to organize and expose subpar merchants through social media and video platforms, indicating a shift towards collective action [9][11]. - There is a growing awareness among consumers about the importance of information literacy, encouraging them to research product reviews and merchant histories before making purchases [9][11]. - The hope remains that consumer backlash will eventually lead to improved market conditions and a return to valuing consumer trust and satisfaction [11].

新闻发布会现场。 4月25日，记者从内蒙古自治区人民政府新闻办召开的"内蒙古自治区优化调整消费品'以旧换新'政策解 读"新闻发布会获悉，今年国家进一步加大消费品"以旧换新"资金支持力度，扩大了补贴支持范围，内 蒙古高度重视，积极推动政策落实，不断取得新进展新成效。一季度，内蒙古社会消费品零售总额同比 增长6.7%。 今年内蒙古发展改革委从三个维度发力，全力推进消费品"以旧换新"工作，确保老百姓享受到"真金白 银"的优惠政策。 完善政策体系。国家今年出台加力扩围实施"两新"通知后，内蒙古发展改革委会同财政厅第一时间印发 内蒙古落实政策、分配下达盟市补贴资金，各有关行业主管部门也陆续印发了分领域补贴细则。近期， 内蒙古发展改革委还会同相关部门联合印发了《内蒙古自治区消费品以旧换新补贴资金全流程管理工作 方案》，进一步明确资金分配、下达、审核、拨付、清算全流程各环节工作要求和时限要求，保障企业 和消费者尽快拿到补贴资金，充分享受到"真金白银"的优惠政策。 加强调研督促。内蒙古发展改革委强化进度管理，按周调度汇总各领域、各盟市补贴资金使用情况，从 不同维度全面细致掌握内蒙古消费品以旧换新工作进展，会同财政厅、商务厅、 ...

证券代码：603883 证券简称：老百姓 公告编号：2025-010 老百姓大药房连锁股份有限公司（以下简称"公司"）于 2024 年 10 月 29 日召开第五届董事会第五次会议和第五届监事会第五次会议，审议通过了《关于 使用部分闲置募集资金暂时补充流动资金的议案》，同意公司使用不超过 15,000 万元暂时闲置的募集资金暂时补充流动资金，使用期限自董事会审议通过之日起 不超过 6 个月。具体内容详见公司于 2024 年 10 月 30 日在上海证券交易所网站 （http://www.sse.com.cn）披露的《关于使用部分闲置募集资金暂时补充流动 资金的公告》。 公司严格按照中国证监会《上市公司监管指引第 2 号上市公司募集资金管理 和使用的监管要求》和上海证券交易所《上市公司自律监管指引第 1 号规范运作》 等相关规定，在使用募集资金暂时补充流动资金期间，对资金进行合理安排，提 高了募集资金的使用效益。 2025 年 2 月 17 日，公司提前归还 5,500 万元至募集资金专用账户。2025 年 4 月 25 日，公司再次归还 9,500 万元至募集资金专用账户，并将上述募集资 金的归还情况通知公司 ...

这是2024年3月25日拍摄的重庆城市景象。新华社记者王全超摄 行走在山城重庆，不仅有两江环绕交汇的澎湃、轻轨穿楼而过的奇景，透过大街小巷、百姓生活的不 同"窗口"观察，"中国式现代化，民生为大"的理念无处不在。 清晨，菜农乘坐被称为"背篓专线"的重庆轨道交通4号线，前往重庆城区的菜市场售卖农产品（2024年3 月27日摄）。新华社记者王全超摄 看温度，从"背篓专线""扁担轮渡"，到打造"15分钟高品质生活服务圈"，于衣食住行细微处，持续增强 公共服务的普惠度、包容性。 "党和政府的一切工作，都是为了老百姓过上更加幸福的生活。"在谱写中国式现代化新篇章的征程中， 山城重庆突出"民呼我为"，聚焦"急难愁盼"，努力把惠民生、顺民意、暖民心的工作做到群众心坎上， 奋力交出一份高分民生答卷！ 4月19日，重庆市九龙坡区谢家湾街道民主村社区居民（右）来到"小黄皮鞋匠"修鞋。 惠民生的力度：接续办好民生实事 在重庆市九龙坡区谢家湾街道民主村社区，创意十足的街边景观与乡愁浓郁的老式建筑巧妙融合，清新 文艺的特色小店与配套齐全的服务设施相得益彰，熙攘的游客、忙碌的创业者、闲适的居民各有所乐， 让这里充满烟火气和幸福感。 两年 ...